Afinitor (everolimus)

pCPA File Number: 20924

Negotiation Status:

Concluded with an LOI

Indication(s):

Neuroendocrine tumours of Gastrointestinal or Lung origin

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0083-000

pCPA Engagement Letter Issued:

2017-03-31

Negotiation Process Concluded:

2017-09-01